European Commission Continues With Mission To Assess Impact of Orphan Regulation
Executive Summary
Companies now have a chance to have their say about their experience of EU Orphan Drug Regulation.
You may also be interested in...
EU Launches Joint Assessment Of Pediatric & Orphan Drugs Legislation
A new European Commission consultation marks the launch of an evaluation exercise to assess the joint impact of the EU pediatric and orphan drugs legislation in supporting the development of pediatric medicines for rare diseases.
Combined Effect Of EU Pediatrics And Orphan Drugs Legislation Under EU Commission Scrutiny
A joint evaluation of the EU pediatrics and orphan drugs legislation is due to commence next year in an effort to understand why the two legal instruments have failed to encourage companies to develop medicines targeting rare diseases in children. The initiative will help decide the possible need for future changes.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.